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Primer	 Common	 Wild	Type	 Mutant	
BclI	 BClI.down.new	 BClI.up.WT.new	 BClI.up.MUT.new	
N363S	 N363.2/4F	 N363S.down.WT.new	 N363S.down.MUT.new	
RS120	 rs12086634.com.f	 rs12086634.wt.r	 rs12086634.mut.r	
RS84	 rs846910.com.r	 RS846910.wt.f	 RS846910.mut.f	
RS770	 rs7701443.gr.com.r	 rs7701443.gr.wt.f	 rs7701443.gr.mut.f	
RS296	 rs2963156.gr.com.r	 rs2963156.gr.wt.f	 rs2963156.gr.mut.f	
TthIII1	 rs10052957.TthIII1.com.f	 rs10052957.TthIII1.wt.r	 rs10052957.TthIII1.mut.r	






























































































































































































































































B-  ELLIS HOSPITAL 
C-  INSTITUTIONAL REVIEW BOARD 
D-  APPLICATION FOR RESEARCH PROJECT 
E-   
F- Project: 
G- Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly 
Obese Patients 
H-  
I- Name, Title and Position of Principal Investigator (s):  
J- Anne Jones, RN 
K-  
L- Co-Investigators:  
M- Brian D. Cohen, PhD, Senior Lecturer, Union College Dept. of 
Biological Sciences 
N-  
O- Purpose of Project: 
P- To characterize the presence of glucocorticoid receptor polymorphisms 
associated with obesity in patients undergoing bariatric surgery 
procedures. 
Q-  
R- Describe Population for Study: 
S- The population for the study will be patients who are preparing for or 
have undergone bariatric surgery procedures for treatment of morbid 
obesity. 
T-  
U- Has  IND # been obtained, if applicable:    ___       IND# _________ 
V- Has NDE # been obtained, if applicable:            NDE#_________ 
W-  
X-  
Y- Probable Time Project May Take: 
Z- Initial studies are projected for 5 months but may extend depending on 
enrollment rate 
AA-  
BB- Probable Starting Date : 
CC- 1/5/14 
DD-  
EE- Potential Hazards and Precautions: 
FF- There are no potential hazards or precautions for the subjects or the 
investigators 
GG-  
HH- Potential Inconveniences or Discomforts to Subjects and Other 
Pertinent Clinical Information: 
II- Subjects will be asked to swish a sterile saline solution in their mouths 
for 30 seconds which some subjects may find unpleasant.   
JJ-  
KK- Estimated Number of Human Subjects Required: 
LL- We are currently targeting 100 subjects as a starting group, although 
we are hoping for a larger subject pool if possible 
MM-  
NN- Estimated Duration of Study: 
OO- Initial study is projected for 5 months, although extension of the 
study may be requested depending on the rate of enrollment of subjects. 
PP-  
QQ- Have You Discussed This Protocol With Other Practitioners 
Affected?   
RR- YES___      NO_X__       If Yes, with Whom? 
SS-  
TT-  
UU- Approval Must be Obtained from the Director of Pharmacy for 
Protocols 
VV- Involving Investigational New Drugs Before IRB Review.  
WW-  
XX- Not Applicable 
YY-         
                                 Director of Pharmacy 
ZZ-  
AAA- Approval Must be Obtained from the Director of Materials 
Management (Purchasing) for Protocols Involving Non-Approved 
Devices or the Purchase of New Devices Before IRB Review. 
BBB-  
CCC- Not Applicable 
DDD-         
           Director of 
Materials Management 
EEE-  
FFF- Source of Funds: 
GGG- Materials for isolating and analyzing patient DNA will be 
provided from the Union College Student Research Grant Fund and the 
Union College Faculty Research Fund 
HHH-  
III- Facilities to be Utilized: 
JJJ- DNA sample, demographic, and clinical information collection will be 
done at the Ellis Bariatric Offices  
KKK- DNA analysis will be done at Union College in Dr. Cohen’s 
research lab. 
LLL-  
MMM- Have you or are you in the process of undertaking training 
or certification in the area of Human Subject Research? 
NNN- Yes _____ No__X___ 
OOO-  
PPP- If Yes, Please provide a copy of the certification with this application. 
QQQ-  
RRR-  
SSS- Do you have any Relationship with the Study Sponsor, Manufacturer 
of the Device or Medication in which you are investigating that should 
be disclosed?  
TTT- Yes _____ No___x__ 
UUU-  
VVV- If Yes, please explain: 
_______________________________________________ 
WWW-  
XXX- Note:  Research that has been approved by the IRB may be 
subject to further appropriate review by Hospital administration if Ellis 
Hospital’s resources are to be utilized in this study. 
YYY-  
















1101 Nott Street    Schenectady, New York 12308   Phone: (518) 243-4011    www.ellismedicine.org 
  
December 23, 2014 
Anne Jones RN 
Brian D Cohen PhD 
Ellis Medicine Bariatric Care Center 
2125 River Road Suite #302 
Niskayuna, NY 12309 
  
Re:  Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly Obese Patients 
  
Dear Ann and Dr. Cohen 
Thank you for attending the December 18, 2014 meeting of the Institutional Review Board. Under 
full board review the protocol, informed consent (with changes) and other materials presented for 
the above mentioned study were approved.  The study was approved for 2 years with an interim 
report due at the June 2015 IRB meeting.  As a reminder, no additional changes may be made to 
this project without first submitting the changes to the IRB for review.  Any inquiries or 
unanticipated problems must also be promptly reported. 
Thank you for your continued interest in medical research. 
Sincerely, 
  Michael V. Pasquarella 
Michael V. Pasquarella Pharm.D., R.Ph. 
Chairperson 
Institutional Review Board 
  






B-	Ellis	Participant	Informed	Consent	Informed	Consent	Form 	The	purpose	of	this	research	project	is	to	look	for	a	correlation	between	polymorphisms	of	the	glucocorticoid	receptor	(variations	in	the	DNA	sequence	of	the	natural	receptor	for	the	hormone	cortisol)	and	clinical	manifestations	of	obesity	and	related	comorbidities	such	as	elevated	blood	sugar,	blood	pressure,	increased	waist/hip	circumference	ratio,	and	altered	serum	lipid	profiles.				Agreeing	to	participate	in	this	study	means	that	you	will	allow	the	testing	of	your	DNA	for	the	purposes	of	 identifying	receptor	variations	and	you	are	agreeing	for	relevant	medical	data	to	be	provided	to	the	researchers	to	compare	with	the	receptor	variations.	You	will	not	receive	information	about	your	individual	results	from	this	study.		Your	DNA	will	not	be	used	for	any	other	purpose	or	analyzed	in	any	other	way.		After	2	years,	your	DNA	sample	will	be	destroyed.		Your	decision	 about	whether	or	not	 to	participate	will	 not	 affect	 your	 treatment	by	Ellis	Bariatric	Medicine.		You	will	not	be	compensated	for	your	participation	in	the	study.		If	you	decide	to	participate	you	will	be	asked	to	perform	a	mouthwash	with	sterile	saline	that	will	allow	us	to	recover	cells	from	inside	your	cheek.		Some	people	find	the	salty	taste	of	the	saline	wash	a	little	unpleasant	but	should	provide	no	significant	discomfort	or	risk	for	you.			Identification	of	which	genetic	variant(s)	of	this	gene	you	have	will	not	affect	your	treatment	in	 any	way.	 	As	 information	 is	 gathered	about	 the	 relationship	between	variations	of	 the	cortisol	 receptor	gene	and	obesity	 (and	 related	diseases),	 it	may	eventually	help	 identify	opportunities	for	complimentary	therapies	for	obesity,	but	this	is	beyond	the	scope	of	the	present	study.	 	Currently	we	are	strictly	interested	in	determining	if	there	is	a	connection	between	this	gene	and	obesity	(and	related	diseases)	and	any	discovery	will	not	affect	your	treatment	plan.		Your	DNA	 sample	will	 be	 coded	with	 your	 patient	 identification	 number	 instead	 of	 your	name	before	it	is	given	to	researchers	at	Union	College	for	DNA	analysis.		The	researchers	will	also	be	given	access	anonymously	to	relevant	medical	information	from	your	records	required	to	complete	the	study.		Records	given	to	Union	College	researchers	will	only	have	your	patient	ID	number	and	not	your	name.		Relevant	medical	information	will	include	but	not	strictly	be	limited	to:	1. Your	weight	before	you	began	treatment	2. Your	height	3. Your	waist	to	hip	ratio	or	waist	circumference	(where	available)	before	you	began	treatment	4. Fasting	blood	sugar	5. Serum	triglycerides	
6. Serum	LDL	and	HDL	7. Blood	pressure	8. Related	medications	that	you	are	taking	that	might	affect	these	measures	9. Treatments	you	receive	at	Ellis	Bariatric	such	as	medications	and	surgical	procedures		Your	DNA	sample	will	be	kept	in	the	laboratory	of	Dr.	Brian	Cohen	at	Union	College	and	will	only	be	accessible	 to	him	or	 to	his	 student	 researchers	working	on	 this	 research	project.	Similarly,	relevant	medical	information	made	available	to	Dr.	Cohen	will	only	be	available	to	him	or	his	student	researchers	and	will	not	be	accessible	to	anyone	else	at	Union	College.				Although	we	do	not	anticipate	making	any	discoveries	that	would	alter	your	care	or	cause	you	to	wish	to	drop	out	of	the	study,	if	any	such	discoveries	are	made	the	medical	staff	of	Ellis	Bariatric	will	contact	you	and	give	you	the	option	to	withdraw	from	the	study.		Choosing	to	withdraw	from	the	study	will	in	no	way	affect	your	care	as	a	patient	of	Ellis	Bariatric.		We	anticipate	that	more	than	100	patients	will	be	a	part	of	the	study	and	the	more	patients	that	are	included,	the	more	significant	any	findings	will	be.				If	 you	have	any	questions,	please	ask	Anne	 Jones,	RN,	CBN,	at	Ellis	Bariatric	or	Dr.	Brian	Cohen,	Union	College.	Their	contact	information	can	be	found	below.		You	will	be	asked	to	sign	one	copy	of	this	informed	consent	form	and	will	be	given	a	copy	to	keep	for	your	records.		The	 choice	 to	 be	 in	 this	 study	 and	 to	 stay	 in	 this	 study	 is	 strictly	 voluntary.	 	Refusal	 to	participate	will	involve	no	penalty	or	loss	of	benefits	which	you	are	otherwise	entitled.	You	may	discontinue	your	participation	at	any	time	with	no	penalty	or	loss	of	benefits	which	you	are	otherwise	entitled.	 	If	you	wish	to	leave	the	study,	please	contact	 	Ms.	Anne	Jones	and	inform	her	that	you	wish	to	withdraw	from	the	study.		You	will	be	asked	to	sign	a	written	form	indicating	your	desire	to	withdraw.	Ellis	Bariatric	will	then	inform	Dr.	Cohen	of	your	ID	number	and	your	DNA	sample	will	be	destroyed	and	your	relevant	medical	information	will	be	removed	from	the	data	set.		Thank	you	for	considering	being	a	part	of	 this	research	study.	 	 If	you	have	any	questions	before	participating	or	at	any	time	during	the	study,	please	do	not	hesitate	to	contact	us.		Anne	Jones,	RN,	CBN	Ellis	Bariatric	Medicine	jonesa@ellismedicine.org	518-831-7030	
Brian	D.	Cohen,	PhD	Union	College	cohenb@union.edu	518-388-8018	Michael	Pasquarella,	PharmD,	RPh	Chair,	Institutional	Review	Board	Ellis	Hospital	pasquarellam@ellismedicine.org	518-243-1818	
 	
1. I	have	been	informed	about	the	purpose	of	this	genetic	test	and	experimental	research	project.		2. I	understand	that	I	will	not	receive	the	results	from	the	testing.		3. I	have	been	informed	as	to	who	may	have	access	to	my	biological	sample,	and	that	the	laboratory	may	retain	any	leftover	sample	until	the	end	of	the	study,	at	which	point	it	will	be	destroyed.		4. I	 have	 read	 the	 material	 provided	 and	 this	 consent	 form	 in	 full.	 My	 questions	 have	 been	answered	to	my	satisfaction.		5. I	consent	to	provide	a	sample	for	genetic	testing	and	to	have	relevant	medical	data	provided	anonymously	to	the	researchers.		6. I	 understand	 that	my	participation	 is	 completely	voluntary	and	 I	may	withdraw	at	 any	 time	without	affecting	my	care	as	a	patient	of	Ellis	Bariatric.				 ______________________________________________________________________________	































































































UNION COLLEGE HUMAN SUBECTS REVIEW COMMITTEE 
2016-2017 APPLICATION TO ENGAGE IN RESEARCH INVOLVING HUMAN SUBJECTS 
 
For full instructions, please visit http://bit.ly/hsrc 
 
Please type your responses in the fields provided.  The grey fields will expand if more space is needed.  When 
completed, please print and deliver to Joshua Hart, Chair of the Human Subjects Review Committee, Bailey 
Hall 302.  Emailed, hand-printed, or unsigned applications will be returned unreviewed.  Blue links can be 
followed by holding the “control” key and clicking. 
 
1a.  Name of student researcher (if applicable)  > Justin Salm  
 Box number  > 1826  
 Email address  > salmj@union.edu  
 Major > Biology 
 
1b. Name of student researcher (if applicable)  > Brianna Godlewski  
 Box number  > 703  
 Email address  > godlewsb@union.edu  
 Major > Biology  
 
2.  Name of faculty researcher or sponsor  > Brian Cohen  
 Office location  > Wold 220  
 Email address  > cohenb@union.edu  
 Department  > Biology  
 
3.  Title of project >  Prevalence of Polymorphisms in the stress related genes in an Undergraduate Population 
 
 
4.   Is this research funded?  > SRG funds requested for materials  
 If yes, by whom?  >   
 
5.  Approximate number of participants:  > 64  
 Approximate age range of participants:  > 18-21    
 Other important characteristics of participants (e.g., prisoners, minors, participants in poor mental or 
 physical health, etc.)  > None  
 
6. Where will the data be collected?  > Union College  
 
7.   If data will be collected at a location other than Union College’s campus, identify how you secured 
permission from the appropriate individuals at the other location(s).  Include this individual’s name and 
contact information.  > N/A  
 
8. How will participants be sampled, recruited, or otherwise enlisted?  > Participants will be BIO 225 Students  
    
 	
9. What rewards, payment, or other credit will be provided for participation, if any?  > None  
 
10. How will the anonymity of participants and/or the confidentiality of the data be ensured?  > The DNA samples 
will be given a random number and students will be asked to transfer the DNA into the new tube so that the tubes will not 
have any other identifying marks.  The number on the DNA sample will be correlated with the form containing information on 
whether the student has previously been diagnosed with depression and the students height and weight.  The form will have 
no identifying information other than the matching number for the DNA sample.  Once filled out, the student will fold the 
form, tape it shut, and hand it to their lab professor.  The lab professor will then give the completed forms and related saliva 
samples to the researchers.  
 
 
For the following items, indicate YES or NO.  If the answer is YES, please explain. 
 
11.   Is it reasonably possible that any of the participants will be placed at risk with regard to physical 
pain or discomfort, psychological stress or discomfort, or social injury (e.g., diminished reputation or 
damaged social or personal relationships)?  >  No  
 
12.   Will information that might affect participants’ willingness to participate be withheld from them 
prior to securing informed consent to take part in the research?  > No  
 
13. Will there be any coercion or penalties that might negate a participant’s freedom to refuse to 
participate in the study or withdraw from participation?  > No  
 
14. Will any of the researchers who will be conducting the study be placed at risk with regard to 
physical or psychological pain, discomfort, or harm?  > No  
 
15. Will any deception be involved?  If so, explain the nature of the deception, the need for the 
deception, and how risks from that deception will be mitigated. > No  
 
16. Will topics or questions about depression or about thoughts of or attempts to engage in of self-
injury or suicide be included?  > Yes.  For part a of this project, the goal is to establish a correlation between 
specific gene polymorphisms in an undergraduate  student population and depression.  For this research, it is 
imperative to know whether the DNA sample belonged to an individual with depression.  However, due to the 
precautions explained in question 10 above, this information can only be related back to the DNA sample, not the 
student.    
 
 
For the following items, indicate YES or NO.  If the answer is NO, please explain. 
 
17. Will all promises and commitments made to the participants regarding their participation be duly 
honored by the researcher?  > Yes  
 
18. Will it be made clear from the onset of the study that participants are free to withdraw from the 
study at any time?  > Yes  
 
 	
19. Immediately following their participation, will all participants be provided with a complete 
explanation (debriefing) of the nature of the study so as to eliminate any possible misconceptions about 
its purpose and to eliminate any stress or discomfort experienced by participants? > Yes  
 
20. If payment is offered, immediately following their participation, will all participants be provided 
with payment as promised (e.g., credit for course, gift certificate, etc) ? > Yes  
 
 
21.  The United States Government, via 45CFR46.116(d), states that informed consent must be obtained from 
participants unless, among other criteria, it is not practicable to do so.   
 
If you do plan to obtain informed consent, please indicate how, whether it be an informed-consent form, 
a clickable button on a Website, or via other documentable means:  > An informed-consent form  
 
If you do not plan to obtain informed consent, please explain how your study meets each of the four 
criteria for waiving this requirement as set forth by 45CFR46.116(d).  > N/A  
  
 
22 (OPTIONAL).  In addition to the specific explanations that may have been provided with the responses to 
items #11 through #21, you are welcome to provide any further comments that might help the Committee 
determine whether the proposed research is likely to produce benefits so significant as to outweigh any 





PLEASE ATTACH THE FOLLOWING APPENDICES. 
 
APPENDIX W:  Briefly explain the purpose of the research and provide a general description of the methods to 
be employed (200 words should be sufficient). 
The	research	attempts	to	examine	the	presence	of	specific	polymorphisms located in the glucocorticoid receptor, the 








 	  
 	
APPENDIX X:  Provide a copy of the informed consent materials you plan to administer to participants (unless 
you have made a case for not using one in #21.  Whether you use the sample form found here or the OHRP 
checklist found here, please ensure that your form contains all the elements called for by OHRP. 
 
 
INFORMED CONSENT FORM 
 
 
Our names are Brianna Godlewski and Justin Salm and we are students at Union College in Schenectady, NY.  We are 
inviting you to participate in a research study.  Involvement in the study is voluntary, so you may choose to participate or 
not.  Participation in the study will not affect your grade in BIO225. Your instructor will not know if you have 
participated or not.  A description of the study is written below. 
 
Our research is interested in determining if there is a relationship between variations in sequences of genes associated 
with stress responses and the prevalence of obesity and depression. You will be asked to provide access to the DNA 
sample that you generated for your BIO225 lab and ask you to answer a few questions including your height and weight 
and if you have ever been diagnosed with depression.  If you choose to participate in the study, we will ask you to put 
your DNA from lab into a new tube labeled with an arbitrary number and also to fill out a separate form marked with the 
same number.  This will take approximately 5 minutes. There are no foreseeable risks to taking part in this study. If you 
no longer wish to continue, you have the right to withdraw from the study, without penalty, at any time.   
 
Your responses will be anonymous: the arbitrary number will not be connected to you in any way so we will not be 
able to identify who filled out each form or whose DNA is being analyzed. 
 
All DNA samples collected will be destroyed after analysis, no later than 7/1/17. 
 




__________________________________  ________________________________ 
 __________________ 
Participant Signature    Printed Name     Date 
		  
 	
APPENDIX Y:  Provide a copy of all materials to be used in your study.  If an interview procedure is to be 
used, a detailed list of the types of questions that will be asked should be described.  If participants will be 
exposed to any stimuli, copies of those stimuli should be presented.  In the case of oral presentations, a 




1. If you choose to participate, please sign the informed consent form. 
2. Regardless of your decision to participate, please fold over the informed consent form, tape it closed, 
and return it to your instructor. This way neither your instructor nor your peers will be able to tell if you 
have chosen to participate. 
3. Please transfer your DNA to the new tube, regardless of whether or not you choose to participate in the 
study. 
4. If you choose to participate in the study, please complete the form below. If you choose not to 
participate in the study, do not complete the form below. 
5. Regardless of your decision to participate, please fold the form over, tape it closed and return this form 
and your DNA to your instructor.  This way neither your instructor nor your peers will be able to tell if 
you have chosen to participate. 





Height (ft and in) _______________     Weight (lbs) _______________ 
 




APPENDIX Z:  Provide a copy of the debriefing to be presented to participants, either in 
text or orally.  A debriefing statement is a statement presented to participants after their 
participation.  It should provide some information about the research study in which they 
just participated.  It need not provide detailed discussions to include literature reviews or 
full hypotheses, but it should provide the participants with at least a basic understanding 
of what the research is about.  If it is not feasible to provide a debriefing, please explain 
why.  
 
Because we will not know which students have chosen to participate, we do not intend to 
provide a debrief.   
	
CERTIFICATION:  I/we certify that: 
  
The statements herein are factual to the best of my/our knowledge; 
I/we have described our methods and materials accurately and completely; 
I/we have not begun data collection in any way and will not do so until given HSRC approval; 
If the proposal is approved, I/we will not make any modifications to the study until receiving additional HSRC 
approval; 
I/we understand that the approval, if granted, expires one year from the initial approval date. 
  
                                                                                                                                                                          
____________________________________ ________________________________ 






















AS Primer Picking Result for SNP2015-01-22 
  

















Sequence Size: 720 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Forward Primer 5': 
ATTCCCGTTGGTTCCGAATA                301     20     61.41     45.00     5.00     2.00 
Mutant Forward Primer 5': 
ATTCCCGTTGGTTCCGAATG                  301     20     64.11     50.00     5.00     2.00 
Common Reverse Primer 5': 
GCTTACATCTGGTCTCATGC                  441     20     55.83     50.00     4.00     2.00 





Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TTCCCGTTGGTTCCGAATA                 302     19     61.21     47.37     5.00     2.00 
Mutant Forward Primer 5': 
TTCCCGTTGGTTCCGAATG                   302     19     64.06     52.63     5.00     2.00 
Common Reverse Primer 5': 
TTACATCTGGTCTCATGCTG                  439     20     54.65     45.00     4.00     2.00 




Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TCCCGTTGGTTCCGAATA                  303     18     59.85     50.00     5.00     2.00 
Mutant Forward Primer 5': 
TCCCGTTGGTTCCGAATG                    303     18     62.86     55.56     5.00     2.00 
Common Reverse Primer 5': 
TTACATCTGGTCTCATGCTG                  439     20     54.65     45.00     4.00     2.00 





:   N363S.new                                                    Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Reverse Primer 5': 
AGATCCTTGGCACCTATTCCATT             342     23     62.17     43.48     4.00     1.00 
Mutant Reverse Primer 5': 
AGATCCTTGGCACCTATTCCATC               342     23     62.67     47.83     4.00     0.00 
Common Forward Primer 5': 
ATACAGCATCCCTTTCTCAA                  242     20     54.87     40.00     3.00     1.00 




Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GATCCTTGGCACCTATTCCATT              341     22     61.38     45.46     4.00     1.00 
Mutant Reverse Primer 5': 
GATCCTTGGCACCTATTCCATC                341     22     61.89     50.00     4.00     0.00 
Common Forward Primer 5': 
AATACAGCATCCCTTTCTCA                  241     20     54.87     40.00     3.00     1.00 




AS Primer Picking Result for rs10052957 
 















Sequence Size: 601 
 
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              2.0 
Max Self Complementarity: 5.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000 
Mispriming Filtering: 'Yes' Form Human Library 
 
Oligo 1 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGATAGATCAGGTCCTTGCCTTGTT           325     25     62.71     44.00     5.00    
 1.00 
Mutant Reverse Primer 5': 
AGATAGATCAGGTCCTTGCCTTGTC             325     25     63.21     48.00     5.00  
   1.00 
Common Forward Primer 5': 
TGAACTCCAGTGTGCCAGAAA                 24     21     61.82     47.62     4.00   
  0.00 
Product Size: 302 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
GATAGATCAGGTCCTTGCCTTGTT            324     24     61.98     45.83     5.00    
 1.00 
 	
Mutant Reverse Primer 5': 
GATAGATCAGGTCCTTGCCTTGTC              324     24     62.48     50.00     5.00  
   1.00 
Common Forward Primer 5': 
GATGAACTCCAGTGTGCCAGA                 22     21     61.28     52.38     4.00   
  3.00 
Product Size: 303 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
ATAGATCAGGTCCTTGCCTTGTT             323     23     60.37     43.48     5.00    
 1.00 
Mutant Reverse Primer 5': 
ATAGATCAGGTCCTTGCCTTGTC               323     23     60.85     47.83     5.00  
   1.00 
Common Forward Primer 5': 
ATGAACTCCAGTGTGCCAGA                  23     20     59.26     50.00     4.00   
  3.00 
Product Size: 301 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
TAGATCAGGTCCTTGCCTTGTT              322     22     60.13     45.46     5.00    
 1.00 
Mutant Reverse Primer 5': 
TAGATCAGGTCCTTGCCTTGTC                322     22     60.63     50.00     5.00  
   1.00 
Common Forward Primer 5': 
ATGAACTCCAGTGTGCCAGA                  23     20     59.26     50.00     4.00   
  3.00 
Product Size: 300 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGATCAGGTCCTTGCCTTGTT               321     21     60.13     47.62     5.00    
 1.00 
Mutant Reverse Primer 5’: 
AGATCAGGTCCTTGCCTTGTC                 321     21     60.64     52.38     5.00  
   1.00 
Common Forward Primer 5': 
GAACTCCAGTGTGCCAGAAA                  25     20     58.85     50.00     4.00   
  0.00 
Product Size: 297 
 	






AS Primer Picking Result for rs6190 
 















Sequence Size: 601 
 
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              2.0 
Max Self Complementarity: 5.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000 
Mispriming Filtering: 'Yes' Form Human Library 
 
Oligo 1 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
TAGAAGTCCATCACATCTCCAT              322     22     56.18     40.91     4.00    
 2.00 
Mutant Reverse Primer 5': 
TAGAAGTCCATCACATCTCCAC                322     22     56.70     45.46     4.00  
   0.00 
Common Forward Primer 5': 
AGGTTCATTTAACAAGCTGC                  120     20     54.71     40.00     5.00  
   3.00 
Product Size: 203 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
 	
AGAAGTCCATCACATCTCCAT               321     21     56.02     42.86     4.00    
 2.00 
Mutant Reverse Primer 5': 
AGAAGTCCATCACATCTCCAC                 321     21     56.55     47.62     4.00  
   0.00 
Common Forward Primer 5': 
AACAAAGAATTTGATTCGGA                  90     20     54.86     30.00     5.00   
  3.00 
Product Size: 232 






:  =ER/EK2                                               Pos.    Len.     Tm   
    GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
GAAGTCCATCACATCTCCAT                320     20     54.73     45.00     3.00    
 2.00 
Mutant Reverse Primer 5': 
GAAGTCCATCACATCTCCAC                  320     20     55.27     50.00     3.00  
   0.00 
Common Forward Primer 5': 
CAAAGAATTTGATTCGGAGT                  92     20     54.44     35.00     5.00   
  3.00 
Product Size: 229 






:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGTCCATCACATCTCCAT                  318     18     50.22     44.44     2.00    
 2.00 
Mutant Reverse Primer 5': 
AGTCCATCACATCTCCAC                    318     18     50.73     50.00     2.00  
   0.00 
Common Forward Primer 5': 
AAGAATTTGATTCGGAGTTA                  94     20     51.70     30.00     5.00   
  3.00 
Product Size: 225 






AS Primer Picking Result for SNP2015-01-23 
  











































Sequence Size: 1956 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   5.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
 	
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Forward Primer 5': 
AGTAGACAAGTTATGTCTGCTGACC           831     25     58.13     44.00     8.00     4.0
0 
Mutant Forward Primer 5': 
AGTAGACAAGTTATGTCTGCTGACG             831     25     59.10     44.00     8.00     4.
00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 




Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
GTAGACAAGTTATGTCTGCTGACC            832     24     57.14     45.83     6.00     4.00 
Mutant Forward Primer 5': 
GTAGACAAGTTATGTCTGCTGACG              832     24     58.16     45.83     6.00     4.00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 




Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TAGACAAGTTATGTCTGCTGACC             833     23     56.23     43.48     6.00     4.00 
Mutant Forward Primer 5': 
TAGACAAGTTATGTCTGCTGACG               833     23     57.29     43.48     6.00     4.00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 




Oligo 4 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
AGACAAGTTATGTCTGCTGACC              834     22     56.07     45.46     6.00     4.00 
Mutant Forward Primer 5': 
AGACAAGTTATGTCTGCTGACG                834     22     57.17     45.46     6.00     4.00 
 	
Common Reverse Primer 5': 
TTGACACCAATTCCTCTCTT                  884     20     54.73     40.00     4.00     0.00 




Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
GACAAGTTATGTCTGCTGACC               835     21     54.85     47.62     6.00     4.00 
Mutant Forward Primer 5': 
GACAAGTTATGTCTGCTGACG                 835     21     56.01     47.62     6.00     4.00 
Common Reverse Primer 5': 
ACTTGAGAACTTGCAGGAAC                  935     20     54.53     45.00     4.00     2.00 






AS Primer Picking Result for rs12086634 
  















Sequence Size: 601 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 57.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   5.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
 	
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Reverse Primer 5': 
AAGAGATGGCTATATTAAGAAATTC           325     25     53.90     28.00     5.00     5.00 
Mutant Reverse Primer 5': 
AAGAGATGGCTATATTAAGAAATTA             325     25     52.46     24.00     4.00     2.0
0 
Common Forward Primer 5': 
TCTGCTGTATCACTGCAGGT                  78     20     56.96     50.00     8.00     4.00 




Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
AGAGATGGCTATATTAAGAAATTC            324     24     52.48     29.17     5.00     5.00 
Mutant Reverse Primer 5': 
AGAGATGGCTATATTAAGAAATTA              324     24     50.98     25.00     4.00     2.00 
Common Forward Primer 5': 
TCTGCAGCTAAGACTGATGC                  54     20     56.88     50.00     6.00     3.00 




Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GAGATGGCTATATTAAGAAATTC             323     23     51.32     30.44     5.00     5.00 
Mutant Reverse Primer 5': 
GAGATGGCTATATTAAGAAATTA               323     23     49.76     26.09     4.00     2.00 
Common Forward Primer 5': 
TGATGCCATTTCTGCTGTAT                  68     20     56.74     40.00     5.00     2.00 




Oligo 4 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
AGATGGCTATATTAAGAAATTC              322     22     49.40     27.27     5.00     5.00 
Mutant Reverse Primer 5': 
AGATGGCTATATTAAGAAATTA                322     22     47.81     22.73     4.00     2.00 
 	
Common Forward Primer 5': 
TCTGCAGCTAAGACTGATGC                  54     20     56.88     50.00     6.00     3.00 




Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GATGGCTATATTAAGAAATTC               321     21     48.01     28.57     5.00     5.00 
Mutant Reverse Primer 5': 
GATGGCTATATTAAGAAATTA                 321     21     46.36     23.81     4.00     2.00 
Common Forward Primer 5': 
TGATGCCATTTCTGCTGTAT                  68     20     56.74     40.00     5.00     2.00 
Product Size: 254 
  
-------------------------------------------------------------------------------------- 
  
	
F-	Gel	Electrophoresis	Protocol	Pouring	an	agarose	gel			
Assembling	the	gel	box	
• Turn	the	gel	box	so	the	electrodes	are	facing	you	
• Place	the	gel	tray	into	the	box	perpendicular	to	the	box	so	that	the	rubber	gaskets	on	the	side	seal	along	the	edge	of	the	box	(figure	1)	
• There	are	2	notches	for	the	combs-	make	sure	one	set	of	notches	is	on	the	far	side	of	the	gel	box	and	one	set	is	closer	to	you	in	the	middle	(see	figure	2)		
Making	the	gel	
• Measure	100ml	1XPE	buffer	with	a	graduated	cylinder	and	place	in	a	500ml	Erlinmeyer	flask	
• Add	1g	of	agarose	
• Swirl,	then	microwave	(for	the	microwave	in	WLDC201	microwave	for	1	minute	and	15	seconds).	 Figure	4	
Figure	3	
 	
• Remove	from	microwave	with	a		hot	glove,	hold	up	to	the	light	and	swirl	to	make	sure	everything	is	dissolved.		
Pouring	the	gel	
• When	the	gel	has	cooled	slightly,	add	10ul	of	ethidium	bromide	solution	to	100ml	of	gel,	swirl,	and	then	pour	into	the	gel	tray.	FROM	THIS	POINT	FORWARD	YOU	MUST	WEAR	GLOVES	WHEN	TOUCHING	THE	GEL	OR	THE	BUFFER	
• Place	combs	into	the	tray-	the	12	well	comb	should	be	at	the	top	of	the	gel	and	the	20	well	comb	in	the	middle.		Both	should	be	pointing	to	1.5mm	
• Allow	the	gel	to	solidify	
• Immediately	wash	the	flask	out	with	hot	water.		Failure	to	do	so	will	result	in	residual	agarose	gelling	in	the	bottom	of	the	flask	in	which	case	you	will	be	severely	mocked	at	lab	meeting.		
Running	the	gel	
• When	the	gel	has	solidified,	turn	the	gel	perpendicularly	so	that	the	12	well	comb	is	on	the	left.	
• Add	sufficient	1XPE	to	the	gel	box	so	that	the	gel	is	completely	submerged	
• Add	40ul	ethidium	bromide	to	the	gel	box	on	the	right	hand	side.	
• Load	samples	onto	the	gel	and	slide	the	lid	on.	
• Connect	the	electrodes	to	the	power	supply	
• Press	the	set	button	and	check	the	current	(pun	intended)	settings.		Make	sure	the	dials	for	Watts	and	Milliamps	are	at	the	max	and	set	the	voltage	with	the	dial.	
• Press	the	start	button	and	the	light	labeled	DC	should	come	on.		A	few	seconds	later	you	should	hear	a	pop	and	a	few	seconds	after	that	you	should	see	bubbles	in	the	gel	box.	
• If	the	DC	light	fails	to	stay	on,	you	may	have	a	bad	connection	somewhere	so	you	should	go	back	and	recheck	them	all.		Sometimes	you	might	need	to	slide	the	lid	off	and	then	back	on	again.		
Figure	5	
Figure	6	
 	
Disposing	of	the	gel	PUT	ON	GLOVES	Remove	the	gel	from	the	tray	and	place	it	on	a	blue	absorbent	pad	in	the	hood.		When	the	gel	has	dried,	place	it	in	the	yellow	waste	can	in	the	common	room	near	the	ice	machine	(WLDC207	Buffer	should	be	poured	down	the	drain	and	the	gel	tray	and	box	should	be	rinsed	with	DI	water	and	placed	back	in	the	drawer			
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